// App-Quantinova.ai

: Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma

Researchers

Presenter

  • Priya Sriskandarajah

Principal Investigators

  • Kevin Boyd

  • Wen Xu

  • Irene Moreno Candilejo

  • Sidra Ellis

  • Amy Price

  • Amy L Sherborne

  • James Croft

  • Vallari Shah

  • Joanna Dawes

  • Mona Parmar

  • Alison Turner

  • Emma Hall

  • Nina Tunariu

  • Juanita S Lopez

  • Johann S. de Bono

  • Udai Banerji

  • Martin Kaiser

Medical Centers

  • The Institute of Cancer Research, Sutton, United Kingdom

  • Department of Virology, Royal Free Hospital, London, United Kingdom

  • The Royal Marsden Hospital, London, United Kingdom

  • Royal Marsden Hospital, Surrey, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Division of Molecular Pathology, The Institute of Cancer Research London, London, United Kingdom

  • Sutton, United Kingdom

  • Institute for Cancer Research, London, United Kingdom

  • Department of Haematology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom

  • Division of Molecular Pathology, The Institute of Cancer Research London, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • RAS mutation

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • RO5126766

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT204007509

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved